Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.56 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.56 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686073 | 0.91 | HPGD (0.75) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| SCHEMBL14391353 | 0.91 | HPGD (0.75) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| SCHEMBL2431695 | 0.91 | HPGD (0.60) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| SCHEMBL20327072 | 0.90 | HTT (0.68) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| SCHEMBL8252217 | 0.90 | HTT (0.68) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| Hydrochloric Acid SCHEMBL5095962 | 0.89 | HPGD (0.72) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| SCHEMBL8518585 | 0.89 | HPGD (0.79) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| SCHEMBL12856491 | 0.89 | HPGD (0.79) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| Hydrochloric Acid SCHEMBL27080322 | 0.88 | HPGD (0.58) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 | |
| SCHEMBL22570087 | 0.88 | ALDH1A1 (0.48) | ALDH1A1HPGDTSHRCHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | claimed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | claimed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | claimed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | claimed |
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | ALDH1A1 4300/4885HPGD 2939/4885TSHR 4114/4885 |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | ALDH1A1 4300/4885HPGD 2939/4885TSHR 4114/4885 |
| US-20100261665-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | ALDH1A1 4300/4885HPGD 2939/4885TSHR 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.